Global Drug Eruptions Treatment Market to Reach USD 7.1 Billion by 2033, Growing at a 6.2% CAGR

The global drug eruptions treatment market is set to experience steady growth over the next decade, according to a newly released report. The market, valued at USD 3.89 Billion in 2023, up from USD 3.66 Billion in 2022, is projected to reach USD 7.1 Billion by the end of 2033, growing at a Compound Annual Growth Rate (CAGR) of 6.2% from 2023 to 2033.

The demand for drug eruptions treatment is expected to increase due to the rising incidence of adverse drug reactions and the growing focus on effective dermatological solutions. With advances in medical research and therapeutic developments, the market for drug eruptions treatment is on a strong growth trajectory.

This steady market expansion presents significant opportunities for pharmaceutical companies, healthcare providers, and researchers focused on developing innovative treatments and managing drug-induced skin reactions.

Drug eruption treatment occurs in about 2-5% of hospitalized patients and more than 1% of outpatients. Adverse medication responses are more common in women, the elderly, and individuals with impaired immune systems.

The best way to cure a drug rash is to discontinue the medicine that is triggering it. After quitting a medication, it may require 5-10 days for the skin to heal and up to 3 weeks for the rashes to entirely resolve. Oral antihistamine tablets such as hydroxyzine, diphenhydramine, loratadine, fexofenadine, cetirizine, or desloratadine for irritation; topical corticosteroids (cortisone) lotions or creams for red, inflamed skin; and topical antimicrobial ointments for open sores are other options.

Competitive Landscape 

Some of the prominent players in the global market for drug eruptions treatment are:

• Anuh Pharma Ltd.
• Avik Pharma
• Pfizer CentreOne
• Hovione
• Bausch Health Companies Inc.
• APOTEX
• Astellas Pharma, Inc.
• Sanofi
• Novartis AG
• SBH Sciences

Some of the prominent developments of the key players in the market are:

• Novartis announced in 2021 that the FDA has given ligelizumab (QGE031) the designation of ‘Breakthrough Therapy’ for the treatment of chronic spontaneous urticaria (CSU), commonly known as chronic idiopathic urticaria (CIU), in individuals who had an unsatisfactory reaction to H1-antihistamine therapy. Ligelizumab (QGE031) is a monoclonal anti-immunoglobulin E (IgE) antibody of the next generation. Ligelizumab is considered to act by inhibiting the IgE/FcRI pathway, which is known to be the main driver of the inflammation reaction in CSU. Ligelizumab against omalizumab is now being studied in Phase III clinical trial programs such as PEARL 1 and PEARL 2. (NCT03580369 and NCT03580356). The clinical studies have enrolled over 2,000 patients from 48 countries worldwide.

A Full Report Overview

Key Companies Profiled

• Anuh Pharma Ltd.
• Avik Pharma
• Pfizer CentreOne
• Hovione
• Bausch Health Companies Inc.
• APOTEX
• Astellas Pharma, Inc.
• Sanofi
• Novartis AG
• SBH Sciences

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube